RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: University of Chicago; National Cancer Institute (NCI)
Suspended - verified August 2010
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, or Nab-Paclitaxel
Conditions: Solid Tumors; Pancreatic Cancer; Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: GSK1120212; Drug: Docetaxel; Drug: Erlotinib; Drug: Pemetrexed; Drug: Carboplatin; Drug: nab-Paclitaxel
Sponsor: GlaxoSmithKline
Not yet recruiting - verified August 2010
Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
Conditions: Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage III Colon Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer
Interventions: Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other: immunoenzyme technique; Biological: modified vaccinia virus ankara vaccine expressing p53
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified August 2010
A Study of Gemcitabine Plus OMP-21M18 as 1st-line Treatment in Subjects With Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: OMP-21M18
Sponsors: OncoMed Pharmaceuticals, Inc.; Novotech (Australia) Pty Ltd
Not yet recruiting - verified August 2010
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Liposome Entrapped Docetaxel (LE-DT)
Sponsor: Neopharm
Recruiting - verified August 2010
Comparison of Metal and Plastic Stents for Preoperative Biliary Decompression
Conditions: Obstructive Jaundice; Pancreatic Cancer
Interventions: Procedure: Metal stent placement in the bile duct; Procedure: Plastic stent
Sponsors: University of Alabama at Birmingham; Yale University; University of Virginia; Beth Israel Deaconess Medical Center
Recruiting - verified August 2010
Trial Comparing Two Techniques of Celiac Plexus Neurolysis for Treatment of Pain in Carcinoma Pancreas
Condition: Pancreatic Cancer
Interventions: Procedure: percutaneous fluoro guided celiac plexus neurolysis; Procedure: EUS guided neurolysis
Sponsor: Asian Institute of Gastroenterology, India
Recruiting - verified August 2010
A Study of R04929097 in Combination With Gemcitabine in Patients With Advanced Solid Tumors
Conditions: Solid Tumors; Locally Advanced Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma
Intervention: Drug: RO4929097
Sponsors: University Health Network, Toronto; National Cancer Institute (NCI)
Recruiting - verified August 2010
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
Condition: Advanced Cancers
Interventions: Drug: Lenalidomide; Drug: Bevacizumab; Drug: Sorafenib; Drug: Temsirolimus; Drug: Lenalidomide; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil
Sponsors: M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified August 2010
AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer
Condition: Adenocarcinoma
Intervention: Drug: AXP107-11
Sponsor: Axcentua Pharmaceuticals AB
Not yet recruiting - verified August 2010
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
Conditions: Pancreatic Neoplasms; Pancreatic Cancer
Intervention: Drug: Gemcitabine and cisplatin
Sponsor: Emory University
Recruiting - verified August 2010
A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic Adenocarcinoma
Condition: Pancreatic Neoplasms
Intervention: Drug: ASG-5ME
Sponsors: Seattle Genetics, Inc.; Agensys, Inc., an affiliate of Astellas Pharma, Inc.
Recruiting - verified August 2010
Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Operable Adenocarcinoma of the Pancreas Phase I - Multiple Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Adenocarcinoma of the Pancreas
Conditions: Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer
Intervention: Drug: siG12D LODER
Sponsor: Silenseed Ltd
Not yet recruiting - verified August 2010
Soluble Triggering Receptor Expressed on Myeloid Cells in Severe Acute Pancreatitis
Conditions: Acute; Pancreatitis
Intervention:
Sponsor: Changhai Hospital
Completed - verified September 2009
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Colorectal Cancer; Kidney Cancer; Lung Cancer; Melanoma (Skin); Ovarian Cancer; Pancreatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: cediranib maleate; Drug: gamma-secretase inhibitor RO4929097; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: CO-1.01; Drug: Gemcitabine
Sponsor: Clovis Oncology, Inc.
Recruiting - verified July 2010
Randomized Study With Oxaliplatin in 2nd Line Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Leucovorin; Drug: OXALIPLATIN; Drug: Capecitabine; Drug: 5-Fluorouracil
Sponsor: Sanofi-Aventis
Recruiting - verified August 2010
Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Gemzar (Gemcitabine); Drug: TH-302; Drug: TH-302
Sponsors: Threshold Pharmaceuticals; PRA International
Recruiting - verified August 2010
Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified August 2010
A Phase II Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Condition: Pancreatic Cancer
Interventions: Drug: Pertuzumab; Drug: Erlotinib
Sponsors: Stanford University; Genentech
Recruiting - verified August 2010
Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers
Conditions: Periampullary Cancers Causing Obstructive Jaundice; Pancreas Head Cancer; Bile Duct Cancer; Ampulla of Vater Cancer
Intervention: Procedure: biliary drainage
Sponsor: Seoul National University Hospital
Not yet recruiting - verified August 2010
A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine
Condition: Pancreatic Cancer
Intervention: Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified August 2010
Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute-Pancreatic Cancer Vaccine
Sponsor: NewLink Genetics Corporation
Recruiting - verified August 2010
Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy
Condition: Pancreatic Cancer
Interventions: Drug: Bortezomib; Drug: Panobinostat
Sponsors: Masonic Cancer Center, University of Minnesota; Novartis Pharmaceuticals; Millennium Pharmaceuticals, Inc.
Recruiting - verified August 2010
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Conditions: Neoplasms, Cystic, Mucinous, and Serous; Pancreatic Neoplasms; Ultrasonography, Interventional
Intervention: Procedure: EUS and/or ERCP with ethanol injections of pancreatic cyst
Sponsor: Mayo Clinic
Recruiting - verified September 2010
Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer
Conditions: Pancreatic Cancer; Colorectal Cancer
Intervention: Biological: Cancer macrobead placement in abdominal cavity
Sponsor: The Rogosin Institute
Recruiting - verified September 2010
A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Drug: Gemcitabine, Bosutinib
Sponsors: University of California, San Francisco; University of Utah
Recruiting - verified August 2010
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Conditions: Pancreatic Cancer; Ductal Adrenocarcinoma; Exocrine Pancreatic Cancer
Intervention: Drug: PCI-27483
Sponsor: Pharmacyclics
Recruiting - verified June 2010
AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Intervention: Drug: AMG 479
Sponsors: Dana-Farber Cancer Institute; Brigham and Women's Hospital; Massachusetts General Hospital; H. Lee Moffitt Cancer Center and Research Institute; Amgen
Recruiting - verified August 2010
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery
Condition: Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: erlotinib hydrochloride; Drug: fluorouracil; Drug: gemcitabine hydrochloride; Radiation: 3-dimensional conformal radiation therapy; Radiation: intensity-modulated radiation therapy
Sponsors: Radiation Therapy Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Early Increase in Blood Flow (EIBS) in the Duodenum in Patients With Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Procedure: Endoscopic Ultrasound (EUS); Device: EUS/4D-ELF
Sponsor: Mayo Clinic
Recruiting - verified September 2010
Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer
Condition: Advanced Pancreatic Cancer
Intervention: Drug: Tarceva, Gemcitabine, Nab-Paclitaxel
Sponsors: OSI Pharmaceuticals; Aptium Oncology Gastrointestinal Cancer Consortium
Recruiting - verified April 2010
Temsirolimus and Bevacizumab in Treating Patients With Locally Advanced, Recurrent, Metastatic, or Progressive Endometrial Cancer, Ovarian Epithelial Cancer, Liver Cancer, Islet Cell Cancer, or Carcinoid Tumor
Conditions: Endometrial Cancer; Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Liver Cancer; Lung Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: temsirolimus; Other: laboratory biomarker analysis
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified September 2010
Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms
Conditions: Neuroendocrine Neoplasms; Thyroid Neoplasms; Parathyroid Neoplasms; Adrenal Neoplasm; Neuroblastoma
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting - verified August 2010
Ultra Sound Guided Fine Needle Aspiration Cytology (FNAC) of Liver and Pancreas Tumours
Conditions: Tumors in Liver; Tumors in Pancreas
Intervention: Procedure: FNAC (fine needle aspiration cytology)
Sponsor: Herlev Hospital
Recruiting - verified July 2009
A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors
Condition: Neoplasms
Interventions: Drug: RG1507; Drug: RAD001
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified August 2010
Study of XL184 in Adults With Advanced Malignancies
Conditions: Solid Tumors; Cancer
Interventions: Drug: XL184; Drug: Placebo; Drug: XL184
Sponsor: Exelixis
Recruiting - verified August 2010
Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Interventions: Drug: Sorafenib; Drug: RAD001
Sponsors: Dana-Farber Cancer Institute; Novartis; Bayer
Active, not recruiting - verified August 2010
Palliative Radiotherapy (RT) for Liver Metastases (Mets) and Hepatocellular Carcinoma (HCC)
Conditions: Hepatocellular Carcinoma; Hepatic Metastasis
Intervention: Radiation: Palliative RT
Sponsor: University Health Network, Toronto
Recruiting - verified August 2010
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Conditions: Cancer; Pancreatic Cancer; Pancreatic Carcinoma
Interventions: Drug: CPI-613; Drug: CPI-613; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine
Sponsor: Cornerstone Pharmaceuticals, Inc.
Recruiting - verified August 2010
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Conditions: Anal Cancer; Carcinoma of the Appendix; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer; Gastrointestinal Carcinoid Tumor; Liver Cancer; Nausea and Vomiting; Pancreatic Cancer; Peritoneal Cavity Cancer; Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride; Other: placebo
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer
Condition: Locally Advanced or Metastatic Pancreatic Cancer
Intervention: Drug: FG-3019
Sponsor: FibroGen
Recruiting - verified August 2010
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Condition: Adenocarcinoma
Interventions: Drug: zoledronic acid; Drug: zoledronic acid; Drug: zoledronic acid; Drug: zoledronic acid
Sponsor: Washington University School of Medicine
Recruiting - verified August 2010
ABT-888 in Treating Patients With Malignant Solid Tumors That Did Not Respond to Previous Therapy
Conditions: brca1 Mutation Carrier; brca2 Mutation Carrier; Breast Cancer; Fallopian Tube Cancer; Hereditary Breast/Ovarian Cancer (brca1, brca2); Ovarian Cancer; Pancreatic Cancer; Peritoneal Cavity Cancer; Prostate Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: veliparib; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: University of Pittsburgh; National Cancer Institute (NCI)
Recruiting - verified January 2010
Prospective Evaluation of the Resection Margins and the Ganglionic Status Using a Quality Standard Resection for Adenocarcinoma of the Head of the Pancreas
Conditions: Pancreas; Adenocarcinoma
Intervention: Procedure: resection of adenocarcinoma of the head of the pancreas
Sponsor: Institut Paoli-Calmettes
Active, not recruiting - verified August 2010
ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: erlotinib [Tarceva]; Drug: capecitabine [Xeloda]
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients
Condition: Metastatic Adenocarcinoma of the Pancreas
Intervention: Drug: capecitabine + erlotinib
Sponsor: Grupo Gallego de Investigaciones Oncologicas
Completed - verified August 2010
A Phase 1b/2 Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer
Conditions: Advanced Cancer; Pancreatic Cancer
Interventions: Drug: ARRY-334543; Drug: Gemcitabine
Sponsor: Array BioPharma
Active, not recruiting - verified August 2010
A Trial of Patients With Metastatic Adenocarcinoma of the Pancreas
Condition: Metastatic Pancreatic Cancer
Interventions: Drug: ABI-007/Gemcitabine; Drug: Gemcitabine
Sponsor: Abraxis BioScience Inc.
Recruiting - verified June 2010
A Study to Test the Safety and Effectiveness of the Experimental Drug, CNTO 328, in Patients With Solid Tumors
Conditions: Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor: Centocor, Inc.
Recruiting - verified August 2010
Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Ipilimumab; Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine
Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting - verified September 2010
Prospective Analysis of Hypersensitivity Reactions to Oxaliplatin
Conditions: Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Small Bowel Cancer; Pancreatic Cancer
Intervention:
Sponsors: Dana-Farber Cancer Institute; Sanofi-Aventis
Recruiting - verified August 2010
Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy
Condition: Tumors
Interventions: Procedure: Pancreaticojejunostomy; Procedure: Pancreaticogastrostomy
Sponsors: University Hospital, Gasthuisberg; Erasme ULB, Brussels; Jolimont, Brussels; St.Lucas, Brugge; AZ.Groeninge, Kortrijk; Universite Catholique Louvain (UCL), Brussels; St.Joseph, Liège; University Hospital, Antwerp; Jan Palfijn, Antwerp; St.Jan, Brugge; Monica, Deurne
Recruiting - verified August 2010
Randomized Trial Comparing Endoscopy and Surgery for Pancreatic Cyst-gastrostomy
Condition: Pancreatic Pseudocysts
Interventions: Procedure: Endoscopic cyst-gastrostomy; Procedure: Surgical cyst-gastrostomy
Sponsor: University of Alabama at Birmingham
Active, not recruiting - verified August 2010
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
Conditions: Neuroendocrine Tumor; Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
Interventions: Drug: SOM230; Drug: RAD001
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; Faulkner Hospital; Novartis
Recruiting - verified August 2010
Efficacy and Safety of Masitinib 9 mg/kg/Day in Combination With Gemcitabine Compared to Placebo in Combination With Gemcitabine in Treatment of Patients With Advanced/Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: masitinib (AB1010); Drug: placebo
Sponsor: AB Science
Active, not recruiting - verified August 2010
AZD0530 in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: AZD0530; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: pharmacological study
Sponsors: Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified October 2009
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
Condition: Advanced Solid Tumors
Interventions: Drug: OSI-906 and/or erlotinib; Drug: OSI-906 and/or erlotinib; Drug: OSI-906 and/or erlotinib
Sponsor: OSI Pharmaceuticals
Recruiting - verified May 2010
Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Procedure: adjuvant therapy; Procedure: neoadjuvant therapy; Procedure: therapeutic conventional surgery
Sponsors: American College of Surgeons; National Cancer Institute (NCI)
Recruiting - verified September 2010
Safety and Exploratory Efficacy of Kanglaite Injection in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Kanglaite Injection plus gemcitabine; Drug: Gemcitabine
Sponsor: KangLaiTe USA
Recruiting - verified September 2010
Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine; Drug: LAG-3 and Gemcitabine; Drug: LAG-3 and gemcitabine; Drug: LAG-3 and gemcitabine; Drug: LAG-3 and gemcitabine
Sponsor: Washington University School of Medicine
Terminated - verified August 2010
Natural Killer Cells and Bortezomib to Treat Cancer
Conditions: Lung or Prostatic Neoplasms; Colorectal or Kidney Neoplasms; Pancreatic Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified June 2010
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Conditions: Breast Cancer; Colorectal Cancer; Head and Neck Cancer; Lung Cancer; Mesothelioma; Pancreatic Cancer; Prostate Cancer; Sarcoma
Interventions: Drug: cisplatin; Drug: pemetrexed disodium; Drug: sorafenib
Sponsor: Masonic Cancer Center, University of Minnesota
Active, not recruiting - verified August 2010
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Erlotinib; Drug: Sorafenib
Sponsors: New York University School of Medicine; Bayer; OSI Pharmaceuticals
Active, not recruiting - verified August 2010
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
Condition: Resistant Solid Malignancies
Intervention: Drug: temsirolimus & docetaxel
Sponsor: Washington University School of Medicine
Recruiting - verified August 2010
Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies
Condition: Resistant Solid Malignancies
Intervention: Drug: temsirolimus & pegylated liposomal doxorubicin
Sponsor: Washington University School of Medicine
Recruiting - verified August 2010
A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Vaccine Therapy and GM-CSF in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Condition: Pancreatic Cancer
Interventions: Biological: falimarev; Biological: inalimarev; Biological: sargramostim
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified August 2008
Standard Pain Control or Intrathecal Therapy in Controlling Pain in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Conditions: Pain; Pancreatic Cancer
Interventions: Drug: morphine sulfate; Device: Medtronic intrathecal pump
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2010
Venous Thromboembolism and Haemostatic Disturbances in Patients With Upper Gastrointestinal Cancer
Conditions: Thrombosis; Deep Venous Thrombosis; Pulmonary Embolism; Venous Thromboembolism; Pancreas Cancer; Esophagus Cancer; Gastric Cancer
Intervention:
Sponsor: University of Aarhus
Recruiting - verified August 2010
A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified August 2010
Safety and Immunogenicity of Human Papillomavirus (HPV) Vaccine in Solid Organ Transplant Recipients
Condition: Transplant
Intervention: Biological: Human papillomavirus quadrivalent vaccine
Sponsor: University of Alberta
Active, not recruiting - verified August 2010
Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified July 2010
A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
Conditions: Adenocarcinoma of the Pancreas; Metastatic Pancreatic Cancer; Pancreatic Cancer
Interventions: Other: Placebo; Drug: AMG 479; Drug: AMG 655
Sponsor: Amgen
Active, not recruiting - verified September 2010
Gemcitabine and Erlotinib With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Condition: Pancreatic Cancer
Interventions: Biological: cixutumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified August 2010
Gemcitabine and Capecitabine to Treat Patients With Advanced Pancreatic and Biliary Cancers
Conditions: Pancreatic Cancer; Biliary Cancer
Interventions: Drug: gemcitabine; Drug: capecitabine
Sponsors: University of California, San Francisco; National Comprehensive Cancer Network
Active, not recruiting - verified August 2010
Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: IMMU-107 (hPAM4)
Sponsor: Immunomedics, Inc.
Recruiting - verified August 2010
Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma
Condition: Diabetes Mellitus
Intervention:
Sponsor: Mayo Clinic
Not yet recruiting - verified August 2010
RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors
Condition: Pancreatic Neuroendocrine Tumor
Interventions: Drug: RAD001; Drug: Temozolomide
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Massachusetts General Hospital; Faulkner Hospital; Novartis; Schering-Plough
Recruiting - verified August 2010
Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine; Drug: Gemcitabine; Drug: Erlotinib; Drug: Oxaliplatin
Sponsors: Hellenic Oncology Research Group; University Hospital of Crete
Recruiting - verified August 2010
Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: panitumumab; Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsors: North Central Cancer Treatment Group; National Cancer Institute (NCI)
Active, not recruiting - verified August 2010
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
Condition: Cancer
Interventions: Drug: fentanyl sublingual spray; Other: questionnaire administration
Sponsor: Insys Therapeutics Inc
Recruiting - verified October 2008
Open-label Study of CS1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: CS-1008 (humanized anti-DR5 antibody); Drug: gemcitabine
Sponsor: Daiichi Sankyo Inc.
Active, not recruiting - verified August 2010
Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Gemcitabine
Sponsors: AstraZeneca; KuDOS Pharmaceuticals Limited
Active, not recruiting - verified August 2010
Identification of Key Blood Molecular Markers for Immunotherapy
Conditions: Carcinomas (Including Squamous Cell and Adenocarcinoma); Anal Cancer; Bile Duct Cancer (Cholangiocarcinoma); Bladder (Urothelial, Transitional Cell) Cancer; Blood and Marrow Transplant (BMT); Bone Cancer; Brain (Nervous System) Cancers; Breast Cancer; Colon/Rectal Cancer; Endocrine Cancer; Esophageal Cancer; Eye Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastro-Esophageal(GE) Junction Cancer; Gastrointestinal Stromal Tumor (GIST); Gynecologic Cancers; Head and Neck Cancers; Hepatobiliary Cancers; Kidney (Renal Cell) Cancer; Leukemia; Lung Cancer; Lymphoma: Hodgkin; Lymphomas: Non-Hodgkin; Mesothelioma; Multiple Myeloma; Myelodysplastic Syndromes (MDS); Myeloproliferative Disorders (MPD); Neuroendocrine Tumors; Pancreatic Cancer; Prostate Cancer; Skin Cancer; Soft Tissue Sarcoma; Testicular Cancer; Thymus Cancer; Thyroid Cancer
Intervention: Procedure: phlebotomy
Sponsor: Stanford University
Recruiting - verified August 2010
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Condition: Cancer
Interventions: Drug: cyclophosphamide; Other: laboratory biomarker analysis; Procedure: biopsy; Procedure: cryosurgery
Sponsors: Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified July 2009
Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: dasatinib; Other: laboratory biomarker analysis; Other: physiologic testing
Sponsors: Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified August 2010
Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.
Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: AG-013736; Drug: Gemcitabine; Drug: Gemcitabine; Drug: placebo
Sponsor: Pfizer
Active, not recruiting - verified August 2010
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis
Sponsor: Roswell Park Cancer Institute
Terminated - verified August 2010
A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Gemcitabine
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified August 2010
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Endocrine Tumors of the Gastrointestinal Tract.
Condition: Neoplasms
Interventions: Drug: bevacizumab [Avastin]; Drug: 5 FU; Drug: Streptozotocin; Drug: Xeloda
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified August 2010
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy
Conditions: Carcinomas (Including Squamous Cell and Adenocarcinoma); Anal Cancer; Bile Duct Cancer (Cholangiocarcinoma); Bladder (Urothelial, Transitional Cell) Cancer; Blood and Marrow Transplant (BMT); Bone Cancer; Brain (Nervous System) Cancers; Breast Cancer; Colon/Rectal Cancer; Endocrine Cancer; Esophageal Cancer; Eye Cancer; Gall Bladder Cancer; Gastric (Stomach) Cancer; Gastro-Esophageal(GE) Junction Cancer; Gastrointestinal Stromal Tumor (GIST); Gynecologic Cancers; Head and Neck Cancers; Hepatobiliary Cancers; Kidney (Renal Cell) Cancer; Leukemia; Lung Cancer; Lymphoma: Hodgkin; Lymphomas: Non-Hodgkin; Mesothelioma; Multiple Myeloma; Myeloproliferative Disorders (MPD); Myelodysplastic Syndromes (MDS); Neuroendocrine Tumors; Pancreatic Cancer; Prostate Cancer; Skin Cancer; Soft Tissue Sarcoma; Testicular Cancer; Thymus Cancer; Thyroid Cancer
Intervention: Procedure: blood draw
Sponsor: Stanford University
Recruiting - verified August 2010
Study of CRLX101 (Formerly Named IT-101) in the Treatment of Advanced Solid Tumors
Conditions: Cancer; Solid Tumor
Intervention: Drug: Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer
Sponsor: Cerulean Pharma Inc.
Recruiting - verified September 2010
Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients
Condition: Pancreatic Cancer
Interventions: Drug: Cetuximab; Drug: Gemcitabine; Drug: Oxaliplatin; Drug: Capecitabine; Radiation: Radiotherapy
Sponsors: M.D. Anderson Cancer Center; Bristol-Myers Squibb
Active, not recruiting - verified August 2010
Hyperthermia With Chemotherapy for Locally Advanced or Metastatic Pancreas Cancer
Condition: Pancreatic Neoplasms
Interventions: Device: Heckel Infrared Radiant Heat Device; Other: cisplatin, gemcitabine, interferon-alpha; Other: thermochemotherapy
Sponsor: The University of Texas Health Science Center, Houston
Recruiting - verified August 2010
Irradiated Donor Lymphocyte Infusion in Treating Patients With Relapsed or Refractory Hematologic Cancer or Solid Tumor
Condition: Cancer
Interventions: Biological: therapeutic allogeneic lymphocytes; Other: laboratory biomarker analysis
Sponsors: Cancer Institute of New Jersey; National Cancer Institute (NCI)
Recruiting - verified May 2009
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
Condition: Cancer
Interventions: Drug: isolated perfusion; Drug: melphalan
Sponsor: National Cancer Institute (NCI)
Active, not recruiting - verified July 2009
CCI-779 in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
Conditions: Gastrointestinal Carcinoid Tumor; Islet Cell Tumor; Lung Cancer; Neoplastic Syndrome
Intervention: Drug: temsirolimus
Sponsors: Princess Margaret Hospital, Canada; National Cancer Institute (NCI)
Active, not recruiting - verified January 2006
Chemotherapy, Interferon Alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: Recombinant Interferon Alfa; Drug: Cisplatin; Drug: Fluorouracil; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI); Schering-Plough
Active, not recruiting - verified August 2010